FPR2 is a therapeutic target in lung cancer

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1142013

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Lung cancer remains the biggest cause of cancer related deaths and chronic smoking is the major risk factor. We have recently demonstrated that a protein termed SAA contributes to damaging inflammation in chronic smokers that develop emphysema through activation of a receptor called FPR2. We will determine whether naturally derived products termed pro-resolving mediators that target this same FPR2 receptor will prove to be a novel and effective treatment for lung cancer.

Funded Activity Details

Start Date: 01-01-2018

End Date: 01-01-2021

Funding Scheme: Project Grants

Funding Amount: $897,979.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Respiratory Diseases

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

G protein-coupled receptors | chronic obstructive pulmonary disease (COPD) | inflammation | lung cancer | tumour immunology

Related Links